<DOC>
	<DOCNO>NCT01605721</DOCNO>
	<brief_summary>Objectives : 1 . To evaluate safety long-term effectiveness coronary stenting XIENCE PRIMETM cohort `` real world '' patient lesion subset . 2 . To determine clinical device procedural success commercial use XIENCE PRIMETM coronary stent Study population : Approximately consecutive 2000 patient treat XIENCE PRIMETM Study period - Patient enrollment : 2011.05 ~ 2012.04 - End follow-up period : 2015 . 02 ( 3 year follow-up ) Primary endpoint : Target Lesion Failure ( TLF ) rate 12 month Secondary endpoint : - In-stent &amp; In-segment Late Loss 9 month - Stent Thrombosis 24 hour ( acute ) , 30 day ( subacute ) , 1 year ( late ) , yearly 3 year ( late ) - Target Vessel Failure 12 month ( composite cardiac death , MI , TVR ) - Any death , cardiac death , MI , TLR , TVR 30 day , 9months , 1 year , 3 year - Composite rate cardiac death MI 3 year - Composite rate death MI 3 year - Composite rate death , MI ( Q-wave non Q-wave ) repeat revascularization 3 year - Compliance therapy interruption prescribe adjunctive antiplatelet therapy 3 year - Procedural success 1 day - Angiographic success 1 day</brief_summary>
	<brief_title>Efficacy Safety Xience Coronary arEry Disease aLL-comers After stENTing Using PRIME Platform ( EXCELLENT-PRIME Registry )</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion Criteria The patient agree participate study sign informed consent form . Alternatively , legally authorize patient representative may agree patient 's participation study sign inform consent form . Angiographic Inclusion Criteria There angiographic inclusion criterion study . Exclusion criterion There exclusion criterion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Everolimus</keyword>
	<keyword>XIENCE PRIME</keyword>
	<keyword>Drug elute stent</keyword>
</DOC>